JP6297582B2 - ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 - Google Patents
ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 Download PDFInfo
- Publication number
- JP6297582B2 JP6297582B2 JP2015542134A JP2015542134A JP6297582B2 JP 6297582 B2 JP6297582 B2 JP 6297582B2 JP 2015542134 A JP2015542134 A JP 2015542134A JP 2015542134 A JP2015542134 A JP 2015542134A JP 6297582 B2 JP6297582 B2 JP 6297582B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxy
- ethyl
- purine
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KTBDFQPHEPDHQW-UHFFFAOYSA-N CC(C)(C)OC(N(CC1O)CC1F)=O Chemical compound CC(C)(C)OC(N(CC1O)CC1F)=O KTBDFQPHEPDHQW-UHFFFAOYSA-N 0.000 description 1
- FPIMVACKDFUNQN-UHFFFAOYSA-N CC(C)(C)OC(NC(CCC1O)C1[IH]C(C)=[IH])=O Chemical compound CC(C)(C)OC(NC(CCC1O)C1[IH]C(C)=[IH])=O FPIMVACKDFUNQN-UHFFFAOYSA-N 0.000 description 1
- YTYSIVBLSXQKNP-AWEZNQCLSA-N CC[n]1c(-c2ccc(C(F)(F)F)nc2)nc2c1ncnc2O[C@@H](CC1)CN1C(N(C1)CC1OC)=O Chemical compound CC[n]1c(-c2ccc(C(F)(F)F)nc2)nc2c1ncnc2O[C@@H](CC1)CN1C(N(C1)CC1OC)=O YTYSIVBLSXQKNP-AWEZNQCLSA-N 0.000 description 1
- HFNOQOKWCDZPFP-UHFFFAOYSA-N CC[n]1c(-c2cnc(C)nc2)nc2c1ncnc2OC(CN(C1)C(OC(C)(C)C)=O)C1F Chemical compound CC[n]1c(-c2cnc(C)nc2)nc2c1ncnc2OC(CN(C1)C(OC(C)(C)C)=O)C1F HFNOQOKWCDZPFP-UHFFFAOYSA-N 0.000 description 1
- LQAYLCLMTRBAPB-UHFFFAOYSA-N CC[n]1ncc(-c([n]2C)nc3c2ncnc3C)c1C Chemical compound CC[n]1ncc(-c([n]2C)nc3c2ncnc3C)c1C LQAYLCLMTRBAPB-UHFFFAOYSA-N 0.000 description 1
- PRFSFXUBDCSISV-UHFFFAOYSA-N CC[n]1ncc(-c([n]2C)nc3c2ncnc3OC(CC2)CC2NC(OC(C)(C)C)=O)c1C Chemical compound CC[n]1ncc(-c([n]2C)nc3c2ncnc3OC(CC2)CC2NC(OC(C)(C)C)=O)c1C PRFSFXUBDCSISV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261727416P | 2012-11-16 | 2012-11-16 | |
US61/727,416 | 2012-11-16 | ||
PCT/CN2013/001394 WO2014075392A1 (en) | 2012-11-16 | 2013-11-15 | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015537010A JP2015537010A (ja) | 2015-12-24 |
JP2015537010A5 JP2015537010A5 (pt) | 2016-12-22 |
JP6297582B2 true JP6297582B2 (ja) | 2018-03-20 |
Family
ID=50730541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015542134A Expired - Fee Related JP6297582B2 (ja) | 2012-11-16 | 2013-11-15 | ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9730940B2 (pt) |
EP (1) | EP2920171B1 (pt) |
JP (1) | JP6297582B2 (pt) |
KR (1) | KR20150082613A (pt) |
CN (1) | CN104918939B (pt) |
AU (1) | AU2013347538B2 (pt) |
BR (1) | BR112015011148A8 (pt) |
CA (1) | CA2891009A1 (pt) |
MX (1) | MX2015006191A (pt) |
RU (1) | RU2658006C2 (pt) |
WO (1) | WO2014075392A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
AU2015226679B2 (en) | 2014-03-06 | 2017-05-25 | Shanghai Haiyan Pharmaceutical Technology Co. Ltd | Piperidine derivatives as orexin receptor antagonist |
CN104030998B (zh) * | 2014-06-05 | 2015-11-18 | 华东师范大学 | 4-多氟烷基-4,5-二取代异噁唑衍生物及其制备方法 |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
AU2015314851B2 (en) | 2014-09-11 | 2020-01-02 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
WO2016057924A1 (en) * | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
EP3411375B1 (en) | 2016-02-04 | 2020-08-05 | Chiesi Farmaceutici S.p.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
WO2017166104A1 (en) * | 2016-03-30 | 2017-10-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
DK3512857T3 (da) * | 2016-09-14 | 2021-05-10 | Janssen Pharmaceutica Nv | Spiro-bicykliske inhibitorer af menin-mll-interaktion |
US10494370B2 (en) * | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
CN113620976B (zh) * | 2020-05-09 | 2023-09-26 | 中国医学科学院药物研究所 | 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物 |
WO2022209916A1 (ja) * | 2021-03-29 | 2022-10-06 | 株式会社カネカ | (2-メチルピリミジン-5-イル)ボロン酸誘導体の製造方法 |
CN113072480B (zh) * | 2021-04-13 | 2022-09-30 | 常州佳德医药科技有限公司 | 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用 |
WO2024083237A1 (en) * | 2022-10-20 | 2024-04-25 | Impact Therapeutics (Shanghai) , Inc | Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT95516A (pt) * | 1989-10-06 | 1991-08-14 | Wellcome Found | Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos |
US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
ES2536972T5 (es) * | 2000-07-21 | 2022-04-06 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos |
SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
KR20060021881A (ko) * | 2003-06-12 | 2006-03-08 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파제의 억제제로서의 사용을 위한 치환된피페리딘 카르바메이트 |
EP1751159A2 (en) | 2004-04-28 | 2007-02-14 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
JP5274460B2 (ja) * | 2006-08-08 | 2013-08-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | E1活性化酵素のインヒビターとして有用なヘテロアリール化合物 |
US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
US8513221B2 (en) | 2008-07-07 | 2013-08-20 | Xcovery Holding, LLC | PI3K isoform selective inhibitors |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
WO2012003264A1 (en) * | 2010-06-30 | 2012-01-05 | Amgen Inc. | Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
TWI617560B (zh) * | 2010-09-14 | 2018-03-11 | 伊塞利克斯公司 | PI3Kδ 抑制劑以及其應用和生產方法 |
EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
CN102838600A (zh) * | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
-
2013
- 2013-11-15 WO PCT/CN2013/001394 patent/WO2014075392A1/en active Application Filing
- 2013-11-15 AU AU2013347538A patent/AU2013347538B2/en not_active Ceased
- 2013-11-15 RU RU2015122895A patent/RU2658006C2/ru not_active IP Right Cessation
- 2013-11-15 EP EP13855335.9A patent/EP2920171B1/en active Active
- 2013-11-15 BR BR112015011148A patent/BR112015011148A8/pt not_active Application Discontinuation
- 2013-11-15 JP JP2015542134A patent/JP6297582B2/ja not_active Expired - Fee Related
- 2013-11-15 CN CN201380070648.XA patent/CN104918939B/zh not_active Expired - Fee Related
- 2013-11-15 KR KR1020157015530A patent/KR20150082613A/ko not_active Application Discontinuation
- 2013-11-15 CA CA2891009A patent/CA2891009A1/en not_active Abandoned
- 2013-11-15 US US14/443,294 patent/US9730940B2/en active Active
- 2013-11-15 MX MX2015006191A patent/MX2015006191A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN104918939A (zh) | 2015-09-16 |
KR20150082613A (ko) | 2015-07-15 |
EP2920171B1 (en) | 2018-08-29 |
CN104918939B (zh) | 2018-08-28 |
CA2891009A1 (en) | 2014-05-22 |
EP2920171A4 (en) | 2016-06-22 |
AU2013347538B2 (en) | 2017-04-27 |
MX2015006191A (es) | 2015-08-10 |
RU2015122895A (ru) | 2017-01-10 |
US20150353552A1 (en) | 2015-12-10 |
JP2015537010A (ja) | 2015-12-24 |
RU2658006C2 (ru) | 2018-06-19 |
BR112015011148A2 (pt) | 2017-07-11 |
EP2920171A1 (en) | 2015-09-23 |
WO2014075392A1 (en) | 2014-05-22 |
AU2013347538A1 (en) | 2015-05-07 |
BR112015011148A8 (pt) | 2019-10-01 |
US9730940B2 (en) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6297582B2 (ja) | ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 | |
JP6322200B2 (ja) | ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 | |
EP3154976B1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
KR20170068585A (ko) | 야누스 키나제 억제제로서의 에틸 N-Boc 피페리디닐 피라졸로 피리돈 | |
AU2014234908A1 (en) | N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors | |
US20240109917A1 (en) | Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors | |
EP3313397B1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
CN116802184A (zh) | 吡唑并噻唑甲酰胺及其作为pdgfr抑制剂的用途 | |
TW202225163A (zh) | 芳香雜環類化合物、藥物組合物及其應用 | |
KR20150130310A (ko) | 야누스 키나제 억제제로서의 같은자리 치환된 시아노에틸피라졸로 피리돈 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161102 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161102 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180123 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6297582 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |